Supernus Pharmaceuticals, Inc.
SUPN
$50.21
$0.300.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -152.19% | -132.02% | 1,131.09% | 499.24% | 5,512.84% |
| Total Depreciation and Amortization | 13.86% | 2.58% | -5.07% | -5.83% | -5.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 252.25% | 40.98% | 33.97% | -23.31% | -41.15% |
| Change in Net Operating Assets | -3,562.72% | -672.78% | -70.93% | -191.45% | 77.54% |
| Cash from Operations | -72.47% | -58.33% | 20.79% | 63.56% | 54.79% |
| Capital Expenditure | -84.55% | -136.13% | -180.52% | -54.32% | -31.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 257.84% | 238.83% | 37.67% | -351.94% | -170.24% |
| Cash from Investing | 102.16% | 117.59% | 36.96% | -345.10% | -170.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 152.32% | 293.91% | 144.60% | 93.28% | 125.54% |
| Repurchase of Common Stock | -55.76% | -200.06% | -106.01% | -63.47% | -36.43% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -25.12% | -12.18% | -381.15% | 97.74% | 103.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,158.31% | 291.35% | 238.25% | 113.15% | 68.32% |